Following its discovery, several studies have used AZ191 in Dyrk1B targeted cancer therapy combined or not with other kinase inhibitors and/or chemo- and radio-therapy approaches [46,63,67,68,75,76,77,78]. This evidence concerns the gene DYRK1B and cancer.